Increased mTOR activation in idiopathic multicentric Castleman disease
© 2020 by The American Society of Hematology..
Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly understood hematologic disorder characterized by lymphadenopathy, systemic inflammation, cytopenias, and life-threatening multiorgan dysfunction. Interleukin-6 (IL-6) inhibition effectively treats approximately one-third of patients. Limited options exist for nonresponders, because the etiology, dysregulated cell types, and signaling pathways are unknown. We previously reported 3 anti-IL-6 nonresponders with increased mTOR activation who responded to mTOR inhibition with sirolimus. We investigated mTOR signaling in tissue and serum proteomes from iMCD patients and controls. mTOR activation was increased in the interfollicular space of iMCD lymph nodes (N = 26) compared with control lymph nodes by immunohistochemistry (IHC) for pS6, p4EBP1, and p70S6K, known effectors and readouts of mTORC1 activation. IHC for pS6 also revealed increased mTOR activation in iMCD compared with Hodgkin lymphoma, systemic lupus erythematosus, and reactive lymph nodes, suggesting that the mTOR activation in iMCD is not just a product of lymphoproliferation/inflammatory lymphadenopathy. Further, the degree of mTOR activation in iMCD was comparable to autoimmune lymphoproliferative syndrome, a disease driven by mTOR hyperactivation that responds to sirolimus treatment. Gene set enrichment analysis of serum proteomic data from iMCD patients (n = 88) and controls (n = 42) showed significantly enriched mTORC1 signaling. Finally, functional studies revealed increased baseline mTOR pathway activation in peripheral monocytes and T cells from iMCD remission samples compared with healthy controls. IL-6 stimulation augmented mTOR activation in iMCD patients, which was abrogated with JAK1/2 inhibition. These findings support mTOR activation as a novel therapeutic target for iMCD, which is being investigated through a trial of sirolimus (NCT03933904).
| Errataetall: |
CommentIn: Blood. 2020 May 7;135(19):1614-1615. - PMID 32379877 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:135 |
|---|---|
| Enthalten in: |
Blood - 135(2020), 19 vom: 07. Mai, Seite 1673-1684 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arenas, Daniel J [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.12.2020 Date Revised 13.11.2023 published: Print ClinicalTrials.gov: NCT03933904 CommentIn: Blood. 2020 May 7;135(19):1614-1615. - PMID 32379877 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2019002792 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307928292 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307928292 | ||
| 003 | DE-627 | ||
| 005 | 20231225130636.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2019002792 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1026.xml |
| 035 | |a (DE-627)NLM307928292 | ||
| 035 | |a (NLM)32206779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arenas, Daniel J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Increased mTOR activation in idiopathic multicentric Castleman disease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.12.2020 | ||
| 500 | |a Date Revised 13.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a ClinicalTrials.gov: NCT03933904 | ||
| 500 | |a CommentIn: Blood. 2020 May 7;135(19):1614-1615. - PMID 32379877 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 by The American Society of Hematology. | ||
| 520 | |a Idiopathic multicentric Castleman disease (iMCD) is a rare and poorly understood hematologic disorder characterized by lymphadenopathy, systemic inflammation, cytopenias, and life-threatening multiorgan dysfunction. Interleukin-6 (IL-6) inhibition effectively treats approximately one-third of patients. Limited options exist for nonresponders, because the etiology, dysregulated cell types, and signaling pathways are unknown. We previously reported 3 anti-IL-6 nonresponders with increased mTOR activation who responded to mTOR inhibition with sirolimus. We investigated mTOR signaling in tissue and serum proteomes from iMCD patients and controls. mTOR activation was increased in the interfollicular space of iMCD lymph nodes (N = 26) compared with control lymph nodes by immunohistochemistry (IHC) for pS6, p4EBP1, and p70S6K, known effectors and readouts of mTORC1 activation. IHC for pS6 also revealed increased mTOR activation in iMCD compared with Hodgkin lymphoma, systemic lupus erythematosus, and reactive lymph nodes, suggesting that the mTOR activation in iMCD is not just a product of lymphoproliferation/inflammatory lymphadenopathy. Further, the degree of mTOR activation in iMCD was comparable to autoimmune lymphoproliferative syndrome, a disease driven by mTOR hyperactivation that responds to sirolimus treatment. Gene set enrichment analysis of serum proteomic data from iMCD patients (n = 88) and controls (n = 42) showed significantly enriched mTORC1 signaling. Finally, functional studies revealed increased baseline mTOR pathway activation in peripheral monocytes and T cells from iMCD remission samples compared with healthy controls. IL-6 stimulation augmented mTOR activation in iMCD patients, which was abrogated with JAK1/2 inhibition. These findings support mTOR activation as a novel therapeutic target for iMCD, which is being investigated through a trial of sirolimus (NCT03933904) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Proteome |2 NLM | |
| 650 | 7 | |a MTOR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.1.1 |2 NLM | |
| 650 | 7 | |a Ribosomal Protein S6 Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a TOR Serine-Threonine Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 700 | 1 | |a Floess, Katherine |e verfasserin |4 aut | |
| 700 | 1 | |a Kobrin, Dale |e verfasserin |4 aut | |
| 700 | 1 | |a Pai, Ruth-Anne Langan |e verfasserin |4 aut | |
| 700 | 1 | |a Srkalovic, Maya B |e verfasserin |4 aut | |
| 700 | 1 | |a Tamakloe, Mark-Avery |e verfasserin |4 aut | |
| 700 | 1 | |a Rasheed, Rozena |e verfasserin |4 aut | |
| 700 | 1 | |a Ziglar, Jasira |e verfasserin |4 aut | |
| 700 | 1 | |a Khor, Johnson |e verfasserin |4 aut | |
| 700 | 1 | |a Parente, Sophia A T |e verfasserin |4 aut | |
| 700 | 1 | |a Pierson, Sheila K |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Wertheim, Gerald B |e verfasserin |4 aut | |
| 700 | 1 | |a Kambayashi, Taku |e verfasserin |4 aut | |
| 700 | 1 | |a Baur, Joseph |e verfasserin |4 aut | |
| 700 | 1 | |a Teachey, David T |e verfasserin |4 aut | |
| 700 | 1 | |a Fajgenbaum, David C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 135(2020), 19 vom: 07. Mai, Seite 1673-1684 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:135 |g year:2020 |g number:19 |g day:07 |g month:05 |g pages:1673-1684 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2019002792 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 135 |j 2020 |e 19 |b 07 |c 05 |h 1673-1684 | ||